JPMorgan on Biohaven Pharmaceutical (BHVN): 'expect the stock to be under some pressure'
Tweet Send to a Friend
JPMorgan analyst Tessa Romero reiterated an Overweight rating and $47.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
